{"name":"Lannett Company","slug":"lannett","ticker":"LCI","exchange":"NYSE","domain":"lannett.com","description":"Lannett Company is a generic pharmaceutical company that focuses on developing and manufacturing generic versions of branded pharmaceuticals. The company has a portfolio of products in various therapeutic areas, including pain management and central nervous system disorders. Lannett's key products include a range of generic pain medications and central nervous system treatments. The company operates in the US market and has a significant presence in the generic pharmaceutical industry.","hq":"Philadelphia, PA","founded":0,"employees":"","ceo":"Timothy C. Crew","sector":"Generic Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":380000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1976-01-01","label":"Ascabin first approved","drug":"Ascabin","drugSlug":"benzyl-benzoate","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Fentanyl Transdermal System patent cliff ($100.0M at risk)","drug":"Fentanyl Transdermal System","type":"patent_expiry","sentiment":"negative"},{"date":"2026-06-01","label":"Hydrocodone Bitartrate and Acetaminophen Tablets patent cliff ($50.0M at risk)","drug":"Hydrocodone Bitartrate and Acetaminophen Tablets","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ascabin","genericName":"BENZYL BENZOATE","slug":"benzyl-benzoate","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Ascabin","genericName":"BENZYL BENZOATE","slug":"benzyl-benzoate","phase":"marketed","mechanism":"Beta-lactamase, Hormone-sensitive lipase","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Lannett Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Lannett Company, Inc. (LCI) today announced its financial results for the fourth quarter and full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Lannett Company Announces Agreement to Acquire Assets from Aurobindo Pharma USA, Inc.","summary":"Lannett Company, Inc. (LCI) today announced that it has entered into an agreement to acquire certain assets from Aurobindo Pharma USA, Inc.","drugName":"","sentiment":"positive"},{"date":"2023-08-15","type":"regulatory","headline":"Lannett Receives FDA Approval for Generic Version of Fentanyl Transdermal System","summary":"Lannett Company, Inc. (LCI) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for a generic version of Fentanyl Transdermal System.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPNkQ1WEVMbElZM3JiMjM4aGZyalR0azBZd1pZRUdMbW9LbWh6MGNBeGFWU0Jra0Z6ZWo5dEJiOVBjZFVBR1U5c2pJUW1iQmtYbkNKZ3ZMdjR6dmhMRWpPd0lXM0xqREVpUGd4SXNPSGVWNGt5b2hMQm94SlY5QWdIRnNzMnhJMFI5Vk5RcjRYYUg3RlJRQVBRZk1FRDdTZEw5MV80dm5PVTB5X3JXNWVYM0hJVkhxOVg4TzhQdFI4WWZWaVhIckF1dGJia0xRTi1SNWh3c2dXcVJja3BPRHAxak1OOGxjalc0?oc=5","date":"2023-04-20","type":"pipeline","source":"PR Newswire","summary":"NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS - PR Newswire","headline":"NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPc0dhVm9QSVRNTU02UmlnS2JIYlc2TWZsQWU1TVd4N3lHWlgwd0sxRi1vUDlkTlhmNHNwYXZQelowT0pCV3ZPQVZxV0h5QVR5WnlpTFYtNHZDak9VbWJGMGhfNU1wbXljTGpCdWFaTGtOSGw3alJNWnY2dkxiR08taWJVUlMxZlRRbTF5VlpoaHhXZTNfSWNiQWdYSjJ6VnlSbFJXS25tQzlQZW1GWFZVeHloanpoYXNFdUQzTTNnR1Y?oc=5","date":"2022-05-12","type":"pipeline","source":"BioSpace","summary":"Lannett Enters Agreement to Be Exclusive U.S. Distributor of Fludarabine Phospate for Injection, USP - BioSpace","headline":"Lannett Enters Agreement to Be Exclusive U.S. Distributor of Fludarabine Phospate for Injection, USP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOQklnNmJIeFUwdnBJOW9tb25JX21LMnRUVk1FX0hxY3JXY2dtNFpPbmpmbG01ZXNzUV9Fa19INnA4cXliNzEwMm5Zakxzd2VsSURpWUJoZHoxS3BsNUNnbm9UcnAxdUIxVHphcmYzWVB5RlZQcnkzVzVzd093UUk5TFBPRVhsaVdGYlQ5UjduR1hDOHpXQXlpd0g4a3lxUzNIUDJuUnRPbUpiMFNwM3pZQ0ltNm5FalhLbnlnUFkySldCWXowUW4ybHpqbw?oc=5","date":"2021-07-29","type":"patent","source":"BioSpace","summary":"LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler - BioSpace","headline":"LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPUzRtcWxvRDFCRldhd3VGVFcyc280SExOZ3VYSUtQY05kbGZPMG1RMUVTRTBHeTl2ME9XdEJhRTA5QTdmT2FWUXEzTF8zWXJKT1FoYVNfejNwbkFSRUZHMHVOMFBZUlZyWHJPeUdOUWUtbFZkQ1FiZi1BMXVISll0bHRZeHhQQXhOaGlzTDU1UU9lSS1IVjB2Nzdud05VRDduN1JtQllYcUZjd1pqclVHRGFnQU50cnF0?oc=5","date":"2020-07-16","type":"regulatory","source":"BioSpace","summary":"Lannett And Cediprof Announce Exclusive Distribution Agreement For An Approved Levothyroxine - BioSpace","headline":"Lannett And Cediprof Announce Exclusive Distribution Agreement For An Approved Levothyroxine","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxONHA5eHdkd1M2Mkl0Wk1MZVl4SmU5UmhrTVZ3aHhSTWNXaWFYTVZNMVEteXVXRWJta3VmbHBrN1J1V2FUMUx3SzhHdGVvVVhRY3JHM1cyQ3l4T0RYczRvY041S0hMZHd3ZEZnd0dHYlNpa0lOeEdGdk1oZTJIT1B6WEZCYXZyVW5OcmZRb3NobUNGQmRJbVdkbzBGWkcybEFQWl9wTXhWVnk3c0sxRldpSVAyTUR6d3RNbUhfQi12eTZZVDFzSlpTdlBn?oc=5","date":"2019-12-23","type":"regulatory","source":"BioSpace","summary":"Lannett Receives FDA Approvals For Two Dosage Strengths Of Butalbital, Acetaminophen And Caffeine Capsules - BioSpace","headline":"Lannett Receives FDA Approvals For Two Dosage Strengths Of Butalbital, Acetaminophen And Caffeine Capsules","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNckZlQTZHLUZ0M0xOZTBUanEyQ0kyRDctOWFKSFJOVnlrM1BZVFFXN0pUWDlRMDlmT2wzRlJGaVRGU1BsQlkzM0dFenZJdlNOcWRxMUpramZOdDZsZWUxMlJ1bXY0V1dhRm5fdHl3dE9GY1RJX1FZaTh5S1hvaTFwVlhNNlp1SnljQzhaY0xB?oc=5","date":"2019-07-08","type":"pipeline","source":"BioSpace","summary":"Lannett Enters Into Distribution Agreement For Levothyroxine - BioSpace","headline":"Lannett Enters Into Distribution Agreement For Levothyroxine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE91NXlYdGd6SHluOEVRaHFuNy1fTDJQcEViQzJWWnFtLWExcmxZQVJ4ejI5VGpRc1Vucm5LRXMtUGJZT2FmSUluV0ZoWlFUUkVncUpvVGh4dkRtYVlxWUh0eGtjZGtFRTZidVUwamFoWkZ1a0F6?oc=5","date":"2019-05-16","type":"patent","source":"BioSpace","summary":"Lannett Begins Marketing Generic Adderall® - BioSpace","headline":"Lannett Begins Marketing Generic Adderall®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOaTVGUmhqUDRyWHk5bXJnQWtGWnU4aU9ycWFqR3NWVE9paGs3WDNMVUZwNUwzdHNGRjFMNTF0MWQ0YmhfRW1hSGc5bVVsSk1JN0lXblhxYTVFODRiR3RnMWpGY2lMWWhqZWdZbFAxcW51TzlWdXFraGhkc01zX2xOQVg5YUZJNWJqc0xUeHd6SklnQQ?oc=5","date":"2019-03-11","type":"patent","source":"BioSpace","summary":"Lannett Enters Into Distribution Agreement For Generic Adderall® - BioSpace","headline":"Lannett Enters Into Distribution Agreement For Generic Adderall®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOY0d3bUVMZ19ydWtSMnE2Q1g4TDVCbnNRWVB0Ull4eXVBR2NvV3FiTjlwTW5OdlNxemNITGZwSTQ1T1MxWmFGMUdKV2l1Tm1VbTIwckdRQ1JKUGhZWlJXTHIxdzBHV3FwYzUxS1FlYWRqY05ZOU13YVBYR0tqUVA3MkxPNmNWd3BKUHVTV1A0eU8wVnFzTEt5NjRBb3BoUVpYYkE?oc=5","date":"2018-11-12","type":"pipeline","source":"BioSpace","summary":"Lannett Enters Into Agreement With Amneal Pharmaceuticals For Levothyroxine - BioSpace","headline":"Lannett Enters Into Agreement With Amneal Pharmaceuticals For Levothyroxine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5IdlI4VWdpMFZacHd5MEJRbkE4QzIzT0tPR3RyUE13OHFqUmJYeVFnbjNzS1dibWg5Sl9YUFlKWDNwNVYtaFhROUN4LXZVdjNnb0NBSjNma3ZwcWhRN0ZLRi1fc1Z6dFFCNjY4MERGcU0yd3hJbktKOA?oc=5","date":"2017-12-21","type":"pipeline","source":"BioSpace","summary":"Lannett Poaches CEO From Cipla North America - BioSpace","headline":"Lannett Poaches CEO From Cipla North America","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOUlN2d1J0dE52MkFiWGhFNzljcFA4M0xIX3l5bUtBMlkzQzhWTGQ2aW1Ha0ZaQjRodVNuWDdVZGZiNldFWnJ0b3diemRUcUxCRHFpaGJyMVV0a2RSVktsUVdpMXNES2p5Q251RXAyT3ZrRklUNlVVa0R1b1BLWmNpQWhzYXhlM3E1ZG9ZYm9tVDRUV0pvU1ZyaHdVUWJHVWlQYV94UF83WlBUZmU1a19YdzFUVGRMdnFwajBLb0l5OWtYOXZEMVRYNXEycUZVaHpJNnFjNm9UNA?oc=5","date":"2015-11-27","type":"pipeline","source":"PR Newswire","summary":"Lannett Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23 Billion - PR Newswire","headline":"Lannett Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPYUJSNl85Q1BTVWhyMTVhdjRtNHNudFhVMldzVVJfZG5yanNGLWhBb1hjTmd2UnpYWE10U2NxRUZQQVNsb25WR1BmOTJHbGNSWms1bjVXTjUxdnJtUi0wNTVxdVVlUVBtWXBQNFBOeWV2bE1QT0JpTm5zMVc2YWFPZE9laDhOblptb29mWVRLSTZpYUZzUk43QnBBY2hvT19fV0tHY2hSQXRrbkd0NVFDMjJBejRlZw?oc=5","date":"2015-06-02","type":"pipeline","source":"PR Newswire","summary":"Lannett Completes Acquisition Of Silarx Pharmaceuticals, Inc. - PR Newswire","headline":"Lannett Completes Acquisition Of Silarx Pharmaceuticals, Inc.","sentiment":"neutral"}],"patents":[{"drugName":"Fentanyl Transdermal System","drugSlug":"fentanyl","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Hydrocodone Bitartrate and Acetaminophen Tablets","drugSlug":"hydrocodone-and-acetaminophen","patentNumber":"","type":"Patent Cliff","expiryDate":"2026-06-01","territory":"US","annualRevenue":50000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":["Teva Pharmaceutical Industries","Mylan N.V.","Endo International plc"],"therapeuticFocus":["Pain Management","Central Nervous System Disorders"],"financials":null,"yahoo":null}